$T2 Biosystems (TTOO.US)$ T2 Biosystems (NASDAQ:TTOO) reported Q3 2024 financial results with total revenue of $2.0 million, up 34% year-over-year. Sepsis test panel revenue reached $1.4 million, also increasing 34%. The company secured 11 T2Dx® Instrument contracts and initiated an exclusive U.S. distribution agreement with Cardinal Health. Net loss was $10.1 million ($0.57 per share), improving from $15.4 million loss in Q3 2023. Cash position stood at $2.1 million as of September 30...
be in twind and rai : Did it fall out?